利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.053 秒)

    Compositions and methods for inhibiting growth of smad4-deficient cancers
    9.
    发明授权
    Compositions and methods for inhibiting growth of smad4-deficient cancers 有权
    用于抑制smad4缺陷型癌症生长的组合物和方法

    公开(公告)号：US07927590B2

    公开(公告)日：2011-04-19

    申请号：US11822859

    申请日：2007-07-10

    申请人： Shelia M. Violette ,  Louise A. Koopman

    发明人： Shelia M. Violette ,  Louise A. Koopman

    IPC分类号： A61K39/395

    CPC分类号： G01N33/5011 ,  A61K38/1793 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/73 ,  G01N33/5091 ,  G01N33/574 ,  G01N33/57407 ,  A61K2300/00

    摘要： The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds and compositions (e.g., antibodies and other ligands that bind αvβ6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such αvβ6-active compounds and compositions by examining the expression of αvβ6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment/prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin αvβ6 on the surfaces of tumor cells and/or that block one or more components of the TGF-β pathway, particularly in smad4-deficient tumor cells.

    摘要翻译： 本发明涉及细胞生物学，免疫学和肿瘤学领域。 本发明涉及在肿瘤抑制基因smad4（也称为dpc4）和整联蛋白αv＆bgr6之间的表达水平与患者群体对αvβb活性化合物和组合物（例如， ，抗体和其他结合αv和bgr的配体; 6），特别是在来自这些患者群体的癌细胞中，更特别地涉及癌如胰腺癌。 因此，本发明提供了通过检查肿瘤细胞的αv＆bgr6和smad4的表达以及诊断方法来确定肿瘤细胞（特别是来自胰腺肿瘤的细胞）对这种αvβb-活性化合物和组合物的反应性的方法 和使用与肿瘤细胞表面上的整联蛋白αv和bgr结合的配体（包括抗体和小分子药物）治疗/预防肿瘤进展和/或阻断TGF-和bgr的一种或多种成分; 途径，特别是在smad4缺陷型肿瘤细胞中。

    Compositions and methods for inhibiting growth of smad4-deficient cancers
    10.
    发明申请
    Compositions and methods for inhibiting growth of smad4-deficient cancers 有权
    用于抑制smad4缺陷型癌症生长的组合物和方法

    公开(公告)号：US20080317667A1

    公开(公告)日：2008-12-25

    申请号：US11822859

    申请日：2007-07-10

    申请人： Shelia M. Violette ,  Louise A. Koopman

    发明人： Shelia M. Violette ,  Louise A. Koopman

    IPC分类号： A61K51/10 ,  A61K39/395 ,  A61K38/43 ,  A61K38/02 ,  A61K38/04 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  A61P35/00 ,  A61K31/282 ,  A61K33/24 ,  A61K31/519 ,  A61K31/505 ,  A61K31/675 ,  A61K31/704 ,  A61K31/195 ,  A61K31/7028 ,  A61K38/00

    CPC分类号： G01N33/5011 ,  A61K38/1793 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/73 ,  G01N33/5091 ,  G01N33/574 ,  G01N33/57407 ,  A61K2300/00

    摘要： The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds and compositions (e.g., antibodies and other ligands that bind αvβ6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such αvβ6-active compounds and compositions by examining the expression of αvβ6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment/prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin αvβ6 on the surfaces of tumor cells and/or that block one or more components of the TGF-β pathway, particularly in smad4-deficient tumor cells.

    摘要翻译： 本发明涉及细胞生物学，免疫学和肿瘤学领域。 本发明涉及以下发现：肿瘤抑制基因smad4（也称为dpc4）和整联蛋白α表达水平的表达水平与患者群体对α-位点活性化合物和组合物的反应性（例如，抗体和其他 特别是在来自这些患者群体的癌细胞中，特别是癌症如胰腺癌的结合的αphavβ6的配体）。 因此，本发明提供了通过检查肿瘤细胞中alphavbeta6和smad4的表达以及诊断和治疗/预防的方法来确定肿瘤细胞（特别是来自胰腺肿瘤的肿瘤细胞）对这种α2β6活性化合物和组合物的反应性的方法 的肿瘤进展，其使用与肿瘤细胞表面上的整联蛋白α1b结合的抗体和小分子药物，和/或阻断TGF-β途径的一个或多个成分，特别是在smad4缺陷型肿瘤细胞中。